Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adagio Therapeutics

4.64
+0.0000
Volume:- -
Turnover:2.47M
Market Cap:504.97M
PE:-1.52
High:4.64
Open:4.64
Low:4.64
Close:4.64
Loading ...

Company Profile

Company Name:
Adagio Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.